50,000 Shares in Certara, Inc. (NASDAQ:CERT) Bought by 272 Capital LP

272 Capital LP acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 50,000 shares of the company’s stock, valued at approximately $586,000.

Several other institutional investors have also added to or reduced their stakes in CERT. Brown Brothers Harriman & Co. bought a new stake in Certara during the 3rd quarter valued at approximately $27,292,000. Sei Investments Co. boosted its position in shares of Certara by 39.5% during the second quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after purchasing an additional 282,357 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares in the last quarter. Daventry Group LP boosted its holdings in shares of Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after buying an additional 791,405 shares in the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC grew its position in shares of Certara by 8.4% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 810,206 shares of the company’s stock worth $11,221,000 after buying an additional 62,912 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Trading Up 3.0 %

Certara stock opened at $11.71 on Friday. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The stock has a fifty day simple moving average of $10.84 and a two-hundred day simple moving average of $12.70. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. During the same quarter last year, the firm posted $0.06 EPS. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. As a group, analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Insider Activity at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.39% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Friday, September 27th. Barclays cut their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Finally, Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.